Invited talk
Advanced Combination Therapies for Pediatric IBD: Rationale and Reality
Elizabeth A. Spencer, MD, MS · Mount Sinai, Icahn School of Medicine
Right Drug, Right Time: Medical Strategies in Pediatric IBD
Learning objectives
- Describe the rationale for using combination or advanced therapies in the management of pediatric IBD.
- Identify potential benefits, risks, and clinical considerations associated with combination treatment approaches.
- Discuss factors that may guide patient selection, treatment monitoring, and optimization of combination therapies.
New special interest group · First meeting
Neurodevelopmental Diagnoses and Gastrointestinal Problems (NDD-GI) SIG
Co-led by our very own Julia Festa, MD.
Add to Google CalendarPoster Session I
- 10
A hidden connection: H-type tracheoesophageal fistula presenting as abdominal distension in a premature infant
Sana Amreen, Yossef Alnasser, Joanne Lai
- 31
Two cases of juvenile polyposis syndrome and Li-Fraumeni syndrome
Likhitha Patlolla, Julia Festa, Stephanie Shea, J. Antonio Quiros
- 37
Standardizing EndoFLIP implementation in pediatric eosinophilic esophagitis: a quality improvement initiative at Mount Sinai Hospital
Shouli Tung, Tzipora Schein, David Dunkin, Joanne Lai, Jan Fune
- 65
Weight-based dupilumab dosing adherence and associated outcomes in pediatric eosinophilic esophagitis
Shouli Tung, Margaret Hofstedt, David Dunkin, Joanne Lai
- 127
Dysmenorrhea in adolescent and young adult females with IBD: characteristics and perceived nonpharmacologic treatment effectiveness
Erica Brenner, Michael Kappelman, Whitney Sunseri, Whitney Gray, Traci Kazmerski, Maureen Kelly, Hilary Michel, Xian Zhang, Hanna Mochida, Ryan Ungaro, Amy Bryant, Elizabeth A. Spencer
- 278*
Pharmacological prophylaxis of post-ERCP pancreatitis in pediatric patients: a network meta-analysis and systematic review
Salma Almotawally, Ahmed Elghamry, Abdul Shahein, Walaa Elfar
Poster Session II
- 439*
Etrasimod efficacy in patients with mildly to moderately active ulcerative colitis: pooled results from the ELEVATE UC and GLADIATOR trials
David Rubin, Marla C. Dubinsky, Andres J. Yarur, Alissa Walsh, Karolina Wosik, John C. Woolcott, Krisztina Lazin, Chuanbo Zhang, Wenjin Wang, Sujatha Menon, Martina Goetsch, Silvio Danese
- 441
Impact of up to 3 years of continuous etrasimod treatment: long-term efficacy results from the ELEVATE UC open-label extension
Bruce E. Sands, Marla C. Dubinsky, Alessandro Armuzzi, Christopher Ma, Irina Blumenstein, Anita Afzali, et al.
Poster Session III
- 645
A nutty case: cashew consumption and recurrent oily stool in young children
Raquela Adelsberg, Joanne Lai
- 681
A rare cause of pediatric hematochezia: rectal lobular capillary hemangioma
Deniz Cataltepe, Stephanie Shea, J. Antonio Quiros
- 695
Case report: a novel presentation of Meckel diverticulum
Jewel Estrella, Lisa Zhang, Joanne Lai
- 760
Massive splenomegaly: an unusual and severe presentation of new-onset autoimmune hepatitis in a teenage girl
Dawei Wu, Jaime Chu, Lesley Small-Harary, Keith J. Breglio
- 762
Progressive hepatic abscesses with hyperinflammation in an adolescent: a case of presumed aseptic abscess syndrome
Lisa Zhang, Angie Buttigieg, Joel Forman, Jaime Chu
- 771
VEO-IBD preceded by immune dysregulation: diagnostic challenges and the limits of genetic testing
Salma Almotawally, Paola Diaz, Shouli Tung, Michelle Bao
- 774
Perceived effectiveness and tolerance of pharmacologic treatments for dysmenorrhea among adolescent and young adult females with inflammatory bowel disease
Erica Brenner, Michael Kappelman, Whitney Sunseri, Whitney Gray, Traci Kazmerski, Maureen Kelly, Hilary Michel, Xian Zhang, Hanna Mochida, Ryan Ungaro, Amy Bryant, Elizabeth A. Spencer
- 812
Failure to achieve treat-to-target endoscopic remission predicts long-term disease progression in pediatric patients with Crohn's disease
Brianna Evans, David Kohler, Nanci Pittman, Keith Benkov, David Dunkin, Joanne Lai, Marla Dubinsky, Elizabeth A. Spencer